Skip to main content
. 2020 Dec 28;24(1):101996. doi: 10.1016/j.isci.2020.101996

Figure 6.

Figure 6

17-DMAG suppresses tumor growth, inhibits tumor angiogenesis, and disrupts multiple oncogenic pathways

(A) Tumor growth curve of Rh30 in CB17 scid mice treated with vehicle (n = 7), 25mg/kg of 17-DMAG (n = 11) and 50mg/kg of 17-AAG (n = 7). Unpaired t test for comparison of tumor volumes of each group. ∗∗p < 0.01, ∗p < 0.05.

(B) Kaplan-Meier analysis of mouse survival treated with vehicle, 17-DMAG and 17-AAG. Log rank test for comparison of survival of each group. (C) RNA-seq read of FGFR4 and MYCN from 3 individual tumors of vehicle, 3 individual tumors of 17-DMAG and 2 individual tumors of 17-AAG.

(D) GSEA analyses of pathways downregulated by 17-DMAG.

(E) GSEA analyses of pathways downregulated by 17-DMAG.

(F) Hematoxylin and Eosin (H&E), cleaved caspase 3 (Cl-CASP3) and TUNEL immunohistochemistry staining of tumor tissue sections from vehicle and 17-DMAG treatment. (G) IHC scores of 3 different areas per section from 4 tumors (n = 12) in each group were compared with unpaired student t test. Data are represented as mean ± SEM.

See also Figures S4 and S5 and Table S3.